FDA

Mar 19, 2019

A New Approach to treat Cystic Fibrosis Researchers at the University of Illinois in Champaign have found that anti-fungal drug amphotericin that helps lung cells to fight chronic bacterial lung infection can help in treating Cystic Fibrosis- a genetic disorder that causes serious damages to lungs. The finding ...

Mar 12, 2019

Stemline gives in-licenses global rights to SL-1001 Stemline Therapeutics, Inc. is a biopharmaceutical company focused on development and commercialization of novel oncology therapeutics, has licensed worldwide rights to a preclinical molecule RET (rearranged during transfection) kinase inhibitor. The RET kinase...

Mar 11, 2019

Technology has made an impact on every field. And Healthcare is no exception. Advances in medical technology have proven to be a game-changer in the health sector. But is the case same when Women healthcare comes to mind? It will not be less than a shock to learn that Women were not included in medical research and...

Mar 08, 2019

Did you know that wearable technology, which consists of sports and activity trackers, accounts for nearly USD 700 Million of the healthcare industry? Moreover, analysts have assessed that the share of Wearable Devices Market is going to hit more than USD 50 Billion, by 2022. A lot of us assume that to track our st...

Mar 06, 2019

US Food and Drug Administration Chief Scott Gottlieb decided to tender his resignation which took everyone by surprise. His departure is a potential blow to the health care industry. Dr.Scott Gottleib – a physician, a medical policy expert, and public health advocate was sworn in as the 23rd Commissioner of FDA. ...

Feb 05, 2019

FDA discards depression drug ALKS 5461 of Alkermes The FDA has rejected approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine and samidorphan. Alkermes designed the combination to act on the mu- and kappa-opioid receptors that eventually showed im...

Jan 17, 2019

Anti-aging startup Juvenescence raises USD 46 Million Juvenescence has bagged the USD 46 million in series B financing. The investment tees the anti-ageing startup to progress the multi-asset pipeline. Jim Mellon, a British billionaire biotech investor, created Juvenescence with early Medivation backer Greg Bai...

Jan 08, 2019

The oral depression drug of Sage Therapeutics meets phase 3 efficacy A phase 3 trial of oral treatment of Sage Therapeutics for postpartum depression (PPD) has hit its primary endpoint. The drug, SAGE-217, showed significant improvements on a depression score and saw no fainting cases. SAGE-217 is an a...

Dec 11, 2018

Axovant tips nelotanserin from small molecule R&D Axovant has stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The dull data compelled Axovant to miss the drug and finish its pivot from small molecules to gene therapies. The parent comp...

Dec 05, 2018

[caption id="attachment_3727" align="aligncenter" width="2322"] FDA[/caption]